Stroke Prevention in Atrial Fibrillation
Top Cited Papers
- 19 May 2015
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA
- Vol. 313 (19), 1950-1962
- https://doi.org/10.1001/jama.2015.4369
Abstract
Importance Atrial fibrillation (AF) is associated with an increase in mortality and morbidity, with a substantial increase in stroke and systemic thromboembolism. Strokes related to AF are associated with higher mortality, greater disability, longer hospital stays, and lower chance of being discharged home than strokes unrelated to AF. Objective To provide an overview of current concepts and recent developments in stroke prevention in AF, with suggestions for practical management. Evidence Review A comprehensive structured literature search was performed using MEDLINE for studies published through March 11, 2015, that reported on AF and stroke, bleeding risk factors, and stroke prevention. Findings The risk of stroke in AF is reduced by anticoagulant therapy. Thromboprophylaxis can be obtained with vitamin K antagonists (VKA, eg, warfarin) or a non-VKA oral anticoagulant (NOAC). Major guidelines emphasize the important role of oral anticoagulation (OAC) for effective stroke prevention in AF. Initially, clinicians should identify low-risk AF patients who do not require antithrombotic therapy (ie, CHA2DS2-VASc score, 0 for men; 1 for women). Subsequently, patients with at least 1 stroke risk factor (except when the only risk is being a woman) should be offered OAC. A patient’s individual risk of bleeding from antithrombotic therapy should be assessed, and modifiable risk factors for bleeding should be addressed (blood pressure control, discontinuing unnecessary medications such as aspirin or nonsteroidal anti-inflammatory drugs). The international normalized ratio should be tightly controlled for patients receiving VKAs. Conclusions and Relevance Stroke prevention is central to the management of AF, irrespective of a rate or rhythm control strategy. Following the initial focus on identifying low-risk patients, all others with 1 or more stroke risk factors should be offered OAC.Keywords
This publication has 101 references indexed in Scilit:
- Faculty Opinions recommendation of Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).Published by H1 Connect ,2016
- Adherence to dabigatran therapy and longitudinal patient outcomes: Insights from the Veterans Health AdministrationAmerican Heart Journal, 2014
- A prospective validation of the SAME-TT2R2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarinInternal and Emergency Medicine, 2014
- Renal Impairment in a “Real-Life” Cohort of Anticoagulated Patients With Atrial Fibrillation (Implications for Thromboembolism and Bleeding)The American Journal of Cardiology, 2013
- Risk of Falls and Major Bleeds in Patients on Oral Anticoagulation TherapyAmerican Journal Of Medicine, 2012
- Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic ReviewAmerican Journal Of Medicine, 2010
- Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification schemeAmerican Heart Journal, 2008
- Independent predictors of stroke in patients with atrial fibrillationNeurology, 2007
- Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial FibrillationAmerican Heart Journal, 2007
- Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)American Heart Journal, 2006